A recent real-world study has provided new insights into the safety of lecanemab, a new FDA-approved therapy for Alzheimer's disease. The study, which involved over 230 patients, found that the therapy's safety and effects on disease progression aligned with results from clinical trials.
Key Insights
Lecanemab is a new FDA-approved therapy designed to remove a protein linked to Alzheimer's disease from the brain. The study found that approximately 80% of patients were able to remain on lecanemab for at least one year, with most treatment-related side effects resolving over time without the need for additional medications or hospitalizations. However, about 1 in 4 patients developed amyloid-related imaging abnormalities (ARIA), a common side effect of the therapy.
